Glioblastoma multiforme (GBM) is a primary brain tumor that is highly malignant. Current treatment options are insufficient in combating the disease with less than 5% of patients living past 5 years from the time of their diagnosis. Fortunately, there are clinical trials recruiting worldwide to find better treatment options that hope to increase the survival rate of individuals affected by GBM. The newly opened trial at Pacific Neuroscience Institute, called The Wizard201G Trial (BBI-DSP7888-201G) from Boston Biomedical Inc., is hoping to do just that.
Boston Biomedical’s trial is a phase 2 study using the investigational drug, DSP-7888, in combination with Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive GBM following initial treatment. Bevacizumab is standard of care for recurrent and progressive GBM and the trial hopes patients will benefit from the addition of DSP-7888.
Unlike most treatment options for GBM, DSP-788 is actually a vaccine. Like many other vaccines, it is injected intradermally. It works by stimulating the immune system to target specific proteins on cancer cells causing them to die. The vaccine works best on patients with specific genes. For this reason, small blood samples are drawn to prescreen patients to make sure they will benefit from participating in the trial.
The trial is currently enrolling. The principal investigator is Santosh Kesari, MD, PhD who was also an investigator on the phase 1 trial which showed a lot of promise.
If you would like to find out more about the trial or any of our other brain tumor clinical trials, please contact us at 310-582-7460.
Najee A. Boucher is a clinical research associate at the Pacific Neuroscience Research Center at Pacific Neuroscience Institute. Along with his colleagues in Dr. Santosh Kesari’s neuro-oncology team, he works in the area of clinical trials research to develop potential therapeutic candidates targeting brain cancer.